BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $15.60.

BCRX has been the topic of a number of research analyst reports. Royal Bank of Canada restated an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $14.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Finally, Barclays boosted their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of large investors have recently made changes to their positions in the business. Deerfield Management Company L.P. Series C lifted its stake in BioCryst Pharmaceuticals by 62.9% in the second quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company’s stock worth $50,279,000 after acquiring an additional 3,140,804 shares during the period. Cubist Systematic Strategies LLC lifted its position in shares of BioCryst Pharmaceuticals by 528.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 1,112,232 shares of the biotechnology company’s stock worth $6,874,000 after purchasing an additional 935,132 shares during the period. Fisher Asset Management LLC boosted its stake in shares of BioCryst Pharmaceuticals by 16.9% during the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock valued at $25,369,000 after purchasing an additional 481,359 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of BioCryst Pharmaceuticals by 472.0% during the third quarter. BNP Paribas Financial Markets now owns 496,784 shares of the biotechnology company’s stock valued at $3,776,000 after buying an additional 409,938 shares during the period. Finally, Principal Financial Group Inc. raised its stake in BioCryst Pharmaceuticals by 1,058.1% in the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock worth $3,127,000 after buying an additional 375,890 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Stock Down 2.9 %

Shares of BCRX opened at $7.61 on Wednesday. The business’s 50-day moving average price is $7.58 and its 200-day moving average price is $7.35. BioCryst Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $8.88. The stock has a market cap of $1.58 billion, a PE ratio of -12.48 and a beta of 1.79.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). The firm had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. The firm’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.19) earnings per share. Analysts expect that BioCryst Pharmaceuticals will post -0.38 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.